1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 1022-1025

  Hou, Duen Ren ^a   Alam, Safiul ^a   Kuan, Ting Chun ^a   Ramanathan, Mani ^a   Lin, Tsung Pang ^b   Hung, Ming Shiu ^b  

^a NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Cannabinoid; Obesity; Triazole

Indexed keywords

1,2,3 TRIAZOLE DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; RIMONABANT;

ARTICLE; BINDING ASSAY; CHEMICAL REACTION; CONFORMATIONAL TRANSITION; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OBESITY; RECEPTOR AFFINITY; TECHNIQUE;

AMIDES; BENZENE; CANNABINOIDS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LIGANDS; MODELS, CHEMICAL; OBESITY; PROTEIN BINDING; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TRIAZOLES;

EID: 58549117673     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.029     Document Type: Article

References (55)

1. Bray G.A. J. Med. Chem. 49 (2006) 4001
2. Olshansky S.J., Passaro D.J., Hershow R.C., Layden J., Carnes B.A., Brody J., Hayflick L., Butler R.N., Allison D.B., and Ludwig D.S. N. Engl. J. Med. 352 (2005) 1138
3. Cooke D., and Bloom S. Nat. Rev. Drug Discov. (2006) 919
4. Report of a WHO Consultation on Obesity: Obesity-Preventing and Managing a Global Epidemic; World Health Organization: Geneva, 2000.
5. Aronne L.J., and Thornton-Jones Z.D. Clin. Pharmacol. Ther. 81 (2007) 748
6. Bishop M.J. J. Med. Chem. 49 (2006) 3999
7. Di Carlo G., and Izzo A.A. Exp. Opin. Invest. Drugs 12 (2003) 39
8. Pertwee R.G. Exp. Opin. Invest. Drugs 9 (2000) 1553
9. Xiang J.-N., and Lee J.C. Annu. Rep. Med. Chem. 34 (1999) 199
10. Trillou R.C., Arnone C., Gonalons N., Keane P., Maffrand J.P., and Soubrie P. J. Physiol. Regul. Integr. Comp. Physiol. 284 (2003) 345
11. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. Pharmacol. Rev. 54 (2002) 161
12. Lange J.H.M., and Kruse C.G. Drug Discov. Today 10 (2005) 693
13. Howlett A.C., Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., and Porrio L.J. Neuropharmacology 47 (2004) 345
14. Carrier E.J., Kearn C.S., Barkmeier A.J., Breese N.M., Yang W., Nithipatikom K., Pfister S.L., Cambell W.B., and Hillard C.J. Mol. Pharmacol. 65 (2004) 999
15. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., and Friedman H. J. Leukoc. Biol. 74 (2003) 486
16. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Berliere J.-C., and le Fur G. FEBS Lett. 350 (1994) 240
17. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C., Soubrie P., Berliere J.-C., and le Fur G. Life Sci. 56 (1995) 1941
18. Mokhopadhyay S., and Howlett A.C. Mol. Pharmacol. 67 (2005) 2016
19. Ruiu S., Pinna G.A., Marchese G., Mussinu J.M., Saba P., Tambaro S., Casti P., Vargiu R., and Pani L. J. Pharmacol. Exp. Ther. 306 (2003) 363
20. Högenauer E.K. Expert Opin. Ther. Patents 17 (2007) 1457
21. Muccioli G.G., and Lambert D.M. Expert Opin. Ther. Patents 16 (2006) 1405
22. Muccioli G.G. Chem. Biodivers. 4 (2007) 1805
23. Hepworth D., Carpino P.A., and Black S.C. Annu. Rep. Med. Chem. 41 (2006) 77
24. Muccioli G.G., Wouters J., Charlier C., Scriba G.K.E., Pizza T., Pace P.D., Martino P.D., Poppitz W., Poupaert J.H., and Lambert D.M. J. Med. Chem. 49 (2006) 872
25. Lang J.H.M., Coolen H.K., van Stuivenberg H.H., Dijksman J.A., Herremans A.H., Ronken E., Keizer H.G., Tipker K., McCreary A.C., Veerman W., Wals H.C., Stork B., Verveer P.C., den Hartog A.P., de Jong N.M., Adolfs T.J., Hoogendoorn J., and Kruse C.G. J. Med. Chem. 47 (2004) 627
26. Lange J.H.M., van Stuivenberg H.H., Veerman W., Wals H.C., Stork B., Coolen H.K.A.C., McCreary A.C., Adolfs T.J.P., and Kruse C.G. Bioorg. Med. Chem. Lett. 15 (2005) 4794
27. Lin L.S., Lanza T.J., Jewell J.J.P., Liu P., Shah S.K., Qi H., Tong X., Wnag J., Xu S.S., Fong T.M., Shen C.-P., Lao J., Xiao J.C., Shearman L.P., Stribling D.S., Rosko K., Strack A., Marsh D.J., Feng Y., Kumar S., Samuel K., Yin W., der Ploeg L.V., Mills S.G., MacCoss M., Goulet M.T., and Hagmann W.K. J. Med. Chem. 49 (2006) 7584
28. Hutst D.P., Lynch D.L., Barnett-Norris J., Hyatt S.M., Seltzman H.H., Zhong M., Song Z.-H., Lewis D., and Reggio P.H. Mol. Pharmacol. 62 (2002) 1274
29. Barth, F.; Congy, C.; Martinez, S.; Rinaldi, M. WO97/19063, 2000.
30. Barth, F.; Casellas, P.; Congy, C.; Martinez, S.; Rinaldi, M. C07D/23114, 1995.
31. Berggren, A. I. K.; Bostrom, S. J.; Cheng, L.; Elebring, S. T.; Greasley, P.; Nagard, M.; Wilstermann, J. M.; Terricabras, E. WO2004058249, 2004.
32. Francis, B.; Christian, C.; Laurent, H.; Murielle, R.-C. WO2006087476, 2006.
33. Francis, B.; Christian, C.; Laurent, H.; Murielle, R.-C. WO2007000505, 2007.
34. Francis, B.; Christian, C.; Jean-Philippe, D.; Murielle, R.-C. WO2006077320, 2006.
35. Francis, B.; Christian, C.; Jean-Philippe, D.; Murielle, R.-C. WO2006084975, 2006.
36. Francis, B.; Christian, C.; Jean-Philippe, D.; Murielle, R.-C. WO2006070106, 2006.
37. Berggren, A. I. K.; Bostrom, S. J.; Elebring, T. S.; Fallefors, L.; Wilstermann, J. M.; Greasley, P. WO2004058255, 2004.
38. Lange J.H.M., van Stuivenberg H.H., Coolen H.K.A.C., Adolfs I.J.P., McCreary A.C., Keizer H.G., Wals H.C., Veerman W., Brost A.J.M., de Looff W., Verveer P.C., and Kruse C.G. J. Med. Chem. 48 (2005) 1823
39. Francis, B.; Murielle, R.-C. WO2007068815, 2007.
40. Plummer C.W., Finke P.E., Mills S.G., Wang J., Tong X., Doss G.A., Fong T.M., Lao J.Z., Schaeffer M.-T., Chen J., Shen C.P., Stribling D.S., Shearman L.P., Strack A.M., and der Ploeg L.H.T.V. Bioorg. Med. Chem. Lett. 15 (2005) 1441
41. Cheng, L. WO2006067428, 2006.
42. Cheng, L. WO2007031721, 2007.
43. Dyck B., Goodfellow V.S., Phillips T., Grey J., Haddach M., Rowbottom M., Naeve G.S., Brown B., and Saunders J. Bioorg. Med. Chem. Lett. 14 (2004) 1151
44. Jagerovic N., Hernandez-Folgado L., Alkorta I., Goya P., Martin M.I., Dannert M.T., Alsasua A., Frigola J., Cuberes M.R., Dordal A., and Holenz J. Eur. J. Med. Chem. 41 (2006) 114
45. Jagerovic N., Hernandez-Folgado L., Alkorta I., Goya P., Navarro M., Serrano A., de Fonseca F.R., Dannert M.T., Alsasua A., Suardiaz M., Pascual D., and Martin M.I. J. Med. Chem. 47 (2004) 2939
46. Pavon F.J., Bilbao A., Hernandez-Folgado L., Cippitelli A., Jagerovic N., Abellan G., Rodriguez-Franco M.I., Serrano A., Macias M., Gomez R., Navarro M., Goya P., and Rodriguez de Fonseca F. Neuropharmacology 51 (2006) 358
47. Francis, B.; Murielle, R.-C. WO2007068814, 2007.
48. Majireck M.M., and Weinreb S.M. J. Org. Chem. 71 (2006) 8680
49. Zhang L., Chen X., Xue P., Sun H.H.Y., Williams I.D., Sharpless K.B., Fokin V.V., and Jia G. J. Am. Chem. Soc. 127 (2005) 15998
50. Mio M.J., Kopel L.C., Braun J.B., Gadzikwa T.L., Hull K.L., Brisbois R.G., Markworth C.J., and Grieco P.A. Org. Lett. 4 (2002) 3199
51. No product was observed when bis(2,4-dichlorophenyl)ethyne 2 was used, and compound 3 gave 57% yield.
52. Previous examples: Tullis, J. S.; Van Rens, J. C.; Natchus, M. G.; Clark, M. P.; De, B.; Hsieh, L. C.; Janusz, M. J. Bioorg. Med. Chem. Lett. 2003, 13, 1665. It is also known that 2-acetyl 1,2,3-triazole is predominated over 1- acetyl isomer under equilibrium. Joule, J. A.; Mills, K. Heterocyclic Chemistry; Blackwell Publishing: Oxford, UK, 2000; p 505.
53. Please see the supporting information for the detailed procedures.
54. The reported CB1/CB2 selectivity of Rimonabant is ∼143, Ref. 12b. Current studies on this issue, see: (a) Tuccinardi, T.; Ferrarini, P. L.; Manera, C.; Ortore, G.; Saccomanni, G.; Martinelli, A. J. Med. Chem. 2006, 49, 984; (b) Lange, J. H. M.; Kruse, C. G.; Van Vliet, B. J. WO2007138050, 2007.
55. The ligand binding models for Rimonabant and SLV319 in the CB1 receptor have been reported, which show the hydrogen bonding acceptor, that is, carbonyl or sulfonyl group, is not located on the same plane of the central core; see Refs. 12c,14a.